- (PLX AI) - Dermapharm board of Management confirmed the outlook for the full year, which forecast an increase of 10-13% in consolidated revenue and of 3-7% in consolidated EBITDA.
- • Co. reports Board of Management and Supervisory Board actions were ratified with large majority at the 2022 Annual General Meeting
- • Shareholders resolve dividend payment of EUR 2.17 per share